MoonLake Immunotherapeutics

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

If you are looking for stocks that are well positioned to maintain their recent uptrend, MoonLake Immunotherapeutics (MLTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going

ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical, a world-leading provider of advanced drug delivery solutions, to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake's Nanobody® sonelokimab.

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

MoonLake Immunotherapeutics: Cosentyx Rival With Numerically Better Data.

MoonLake Immunotherapeutics: Cosentyx Rival With Numerically Better Data

MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually.

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

MoonLake Immunotherapeutics (MLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody ® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeu tics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeutics to i nitiate g lobal Phase 2 s tudy of the Nanobody ® s onelokimab in p atients with active psoriatic arthritis

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class agent for multiple inflammatory disorders.  As per the analysts, MoonLake possesses a possibly best-in-class agent.

HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders

Shares of clinical-stage biotech stock rose nearly $3 a share from Friday's close.

Why MoonLake Immunotherapeutics Stock Shot Up 41.1% on Tuesday

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares are trading approximately 23% higher Tuesday morning on high volume. MoonLake's average session volume over a 100-day period is about 158,900, according to data from Benzinga Pro.

Why MoonLake Immunotherapeutics Shares Are Surging Higher Today

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

News for MoonLake Immunotherapeutics Stock (MLTX)